Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 6,193 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Type 2 Diabetes Mellitus, Serious Mental Illness, Schizophrenia, Major Depression, Bipolar Disorder
Interventions: Lifestyle MIND; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non-Proliferative Diabetic Retinopathy
Interventions: Faricimab; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Bakersfield, California • Modesto, California • Orlando, Florida + 13 more

Conditions: Obesity, Morbid, Obesity, Decision Aids, Bariatric Surgery
Interventions: Video Decision Aid, Booklet Decision Aid; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 20 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity, Morbid, Ventilator-Induced Lung Injury, Respiratory Failure
Interventions: Esophageal balloon, Intervention Spontaneous Breathing Trial (SBT) and Extubation, Control Spontaneous Breathing Trial and Extubation, Intervention Weaning after Tracheostomy, Control Weaning after Tracheostomy; Device · Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Greenville, North Carolina

Conditions: Opioid-use Disorder, Sleep
Interventions: Suvorexant, Suvorexant Placebo; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Respiratory Syncytial Virus Infections
Interventions: Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection); Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more

Conditions: Sleep, Endometrial Neoplasms, Pain
Interventions: zolpidem, sugar pill; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Barretts Esophagus With Dysplasia
Interventions: Alginates; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Smoking Cessation
Interventions: Contingency management, Nicotine replacement therapy, Varenicline, Additional behavioral support; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alcoholism, Substance-related Disorders, Dual Diagnosis
Interventions: Combined Recovery Program, Stable & Able (S&A); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity
Interventions: Pathways; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 1,005 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Alhambra, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Itepekimab SAR440340, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 59
States / cities: Phoenix, Arizona • Fresno, California • Palm Springs, California + 49 more

Conditions: Human Immunodeficiency Virus
Interventions: Baricitinib 2 MG Oral Tablet, Placebo; Drug
Lead sponsor: William Tyor; Other
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Allergic Conjunctivitis
Interventions: Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Cardiovascular Diseases
Interventions: Point of Care, Population Management; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • DeKalb, Illinois • Oak Brook, Illinois + 2 more

Conditions: Communication
Interventions: Communication Skills Training, Profile feedback, Maslach burnout inventory, Emotion Regulation Skills Question (ERSQ), Semi-structured interview, Priming; Behavioral · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Transplants and Implants
Interventions: Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 19 Years to 74 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Emphysema
Interventions: Spiration Valve System, Medical Management; Device · Other
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 40 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 32
States / cities: Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 Inhibitor (DPP-4), Glucagon-Like Peptide-1 Agonist (GLP-1), Thiazolidinedione (TZD), Sulfonylureas, Insulin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25,358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Trevose, Pennsylvania

Conditions: Depression
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Long Beach, California • Minneapolis, Minnesota • Portland, Oregon

Conditions: Plantar Fascitis
Interventions: Radial shockwave therapy, Focused shockwave therapy, Shockwave therapy device, Home therapy; Procedure · Device · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 100 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Prescription Drug Abuse
Interventions: MyHealthyChoices, Health Risk Assessment; Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Morgantown, West Virginia

Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: Education and Reminders, Educational Visit, Medication Educational Visit, Financial Support; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Search by objective public record fields.

Lifestyle MIND- Feasibility of Wait-list Control

Safety and Efficacy of Faricimab in Patients With NPDR

Study Testing Patient Decision Tools Related to the Risks and Benefits of Weight Loss Surgery

Providing Optimal PEEP During Mechanical Ventilation for Obese Patients Using Esophageal Balloon

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Sleep and Endometrial Cancer

The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus

A Smoking Cessation Intervention for Yale Dining Employees

CRP and S&A for Inpatient Veterans

Translational Obesity Research

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Baricitinib for Reduction of HIV - CNS

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Healthy Hearts in the Heartland

Emotion Regulation and Burnout Impact on Communication Documentation

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Genetic and Biochemical Markers of Interferon-Induced Depression.

Shockwave Therapy for Plantar Fasciitis RCT

Using m-Health Tools to Reduce the Misuse of Opioid Pain Relievers

Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)